Targeting the EGFR and c-Met Tyrosine Kinase Receptors in Myeloproliferative Neoplasms

我们认为，在称为骨髓增生性肿瘤(MPN)的血液疾病中，存在着影响血细胞表面受体功能的重要变化。这些变化将扰乱血细胞的产生，并可能成为药物的有效靶点。我们将使用实验室和小鼠模型的MPN以及目前临床上使用的抑制关键受体活性的特定药物来测试这一点。这种方法可以迅速转化为临床试验。

We propose that in the blood disorders called Myeloproliferative Neoplasms (MPN) there are important changes that affect the function of receptors expressed on the surface of blood cells. These changes will perturb blood cell production and may be able to be targeted effectively with drugs. We will test this using laboratory-based and mouse models of MPN, together with specific drugs that are currently in the clinic, and that inhibit the activity of the key receptors involved. This approach can be rapidly translated to clinical trial.